BioWorld

July 28, 2003

View Archived Issues

Fourth Approval For Enbrel: Amgen Adds Spinal Arthritis

As expected, Amgen Inc. and Wyeth Pharmaceuticals won marketing clearance from the FDA for Enbrel (etanercept) against ankylosing spondylitis, or arthritis of the spine. (BioWorld Today) Read More

Vertex Still Expects Approval Of 908 Despite Missed Main Endpoint

Read More

Pain Perception Arises In Remote Region Of Brain's Cerebral Cortex; Gene Therapy Trial Back-Burnered

Read More

House Passes Bill That Would Allow Reimportation Of Drugs

Read More

Chiron Sells $450M In Notes To Replenish Cash Position

Read More

Roche Secures Rights To Origen Via $1.4B Purchase From IGEN

Read More

Other News To Note

Read More

Appointments And Advancements

Read More